Peptide Injected Into the Body Reaches the Eye and Protects Nerve Cells From Glaucoma Damage

Multi-model preclinical study. Researchers tested peptain-1 in cultured rat retinal ganglion cells, rat retinal explants, a mouse ischemia/reperfusion injury model, and a rat model of chronic elevated intraocular pressure (5 weeks). Peptain-1 was administered via intraperitoneal injection. Retinal penetration was confirmed using a fluorescent-labeled version (Cy7 conjugate). RGC survival, axonal transport, and mitochondrial protein levels were measured.

Glaucoma is the leading cause of irreversible blindness worldwide, and the only current treatment is lowering eye pressure — which doesn't work for everyone and doesn't directly protect the dying nerve cells. Peptain-1 represents a fundamentally different approach: directly protecting the retinal ganglion cells that glaucoma destroys. The fact that it works when injected systemically (not into the eye) and crosses the blood-retinal barrier makes it far more practical than eye-injection-only therapies.

Neuroprotection has been the holy grail of glaucoma research for decades. While lowering eye pressure helps, many patients continue to lose vision because the underlying nerve cell death isn't addressed. Peptain-1 joins a growing list of neuroprotective peptides being investigated for eye disease, but its ability to cross the blood-retinal barrier after systemic injection sets it apart. If it reaches human trials, it could be the first neuroprotective therapy for glaucoma — a fundamentally different treatment than anything currently available.

Animal models only — rodent glaucoma models don't perfectly replicate the slow, chronic disease seen in humans over decades. Dosing details and duration of protective effect after stopping treatment were not described. Long-term safety of systemic peptain-1 was not assessed. The study doesn't address whether the peptide would work in human eyes, which have different blood-retinal barrier properties.